A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: Effects on 24-h intragastric pH

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 11, 2001, Pages 1807-1817

  Taubel J J ^a   Sharma, V K ^b   Chiu, Y L ^c   Lukasik, N L ^d   Pilmer, B L ^d   Pan, W J ^c,e  

^a Charterhouse Clinical Research Unit   (United Kingdom)

^b MAYO CLINIC   (United States)

^c ABBOTT LABORATORIES   (United States)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^e ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PANTOPRAZOLE; PROTIUM IV;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; BENZIMIDAZOLES; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HUMANS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; INTUBATION, GASTROINTESTINAL; MIDDLE AGED; OMEPRAZOLE; SULFOXIDES; SUSPENSIONS;

EID: 0034772365     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01098.x     Document Type: Article

References (28)

1. Acid suppression in duodenal ulcer: A meta-analysis to define optimal dosing with antisecretory drugs
2. Is there an optimal degree of acid suppression for healing of duodenal ulcer? A model of the relationship between ulcer healing and acid suppression
3. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
4. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
5. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers
6. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion
7. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring
8. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion, and serum gastrin in healthy volunteers
9. Influence of lansoprazole 15 mg and omeprazole 20 mg and 40 mg on meal-stimulated gastric acid secretion
10. Comparison of the effects of lansoprazole and omeprazole on 24-hour gastric pH in normal male volunteers
11. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole
12. Pharmacokinetics and metabolism of omeprazole in man
13. Lansoprazole: An alternative method of administration of a capsule dosage formulation
14. Lansoprazole: Administration of the contents of a capsule dosage formulation through a nasogastric tube
15. The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules
16. Alternative methods of proton pump inhibitor administration
17. A study of the effects of per-gastrostomy administration of an alkaline suspension of omeprazole on intragastric acidity
18. Nonencapsulated intact granule omeprazole is effective in gastric acid suppression
19. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole
20. Simplified lansoprazole suspension - A liquid formulation of lansoprazole - Effectively suppresses intragastric acidity when administered through a gastrostomy
21. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose-response study
22. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole
23. The GLM procedure
24. Twenty-four hour monitoring of intragastric acidity: Comparison between lansoprazole 30 mg and pantoprazole 40 mg
25. Lansoprazole or pantoprazole: Which PPI provides faster and more profound acid suppression?
26. Lansoprazole achieves faster control of intragastric acidity than pantoprazole
27. Effects on 24-hour intragastric pH: A comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously
28. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects